Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 40 | 2025 | 1193 | 10.780 |
Why?
|
| Primary Health Care | 20 | 2024 | 356 | 5.920 |
Why?
|
| Diabetes Mellitus | 19 | 2023 | 746 | 4.230 |
Why?
|
| Hypoglycemic Agents | 16 | 2025 | 358 | 3.820 |
Why?
|
| Psychiatry | 4 | 2023 | 83 | 3.080 |
Why?
|
| Blood Glucose | 14 | 2024 | 846 | 2.910 |
Why?
|
| Depression | 9 | 2024 | 517 | 2.580 |
Why?
|
| Diabetes Complications | 12 | 2024 | 172 | 2.360 |
Why?
|
| Physicians | 7 | 2022 | 690 | 2.200 |
Why?
|
| Mass Screening | 7 | 2024 | 646 | 2.130 |
Why?
|
| Patient Portals | 2 | 2024 | 18 | 1.750 |
Why?
|
| Qualitative Research | 3 | 2024 | 312 | 1.730 |
Why?
|
| Aging | 10 | 2023 | 727 | 1.690 |
Why?
|
| Humans | 105 | 2025 | 90529 | 1.670 |
Why?
|
| Medicaid | 7 | 2022 | 242 | 1.590 |
Why?
|
| Mental Health Services | 3 | 2024 | 59 | 1.530 |
Why?
|
| Cost Sharing | 4 | 2024 | 17 | 1.450 |
Why?
|
| Hypothyroidism | 5 | 2024 | 248 | 1.430 |
Why?
|
| United States | 26 | 2024 | 7137 | 1.380 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2024 | 59 | 1.370 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 722 | 1.220 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 532 | 1.180 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 3 | 2023 | 40 | 1.170 |
Why?
|
| Nutrition Surveys | 7 | 2023 | 111 | 1.170 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 433 | 1.140 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 64 | 1.120 |
Why?
|
| Documentation | 3 | 2022 | 103 | 1.110 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 168 | 1.100 |
Why?
|
| Physicians, Primary Care | 2 | 2020 | 104 | 1.060 |
Why?
|
| Interviews as Topic | 3 | 2024 | 344 | 1.010 |
Why?
|
| Adult | 29 | 2024 | 26922 | 0.970 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 1735 | 0.940 |
Why?
|
| Female | 48 | 2025 | 46825 | 0.940 |
Why?
|
| Male | 46 | 2025 | 42905 | 0.930 |
Why?
|
| Aged | 36 | 2025 | 19380 | 0.920 |
Why?
|
| Middle Aged | 33 | 2024 | 26305 | 0.870 |
Why?
|
| Hormone Replacement Therapy | 3 | 2024 | 85 | 0.860 |
Why?
|
| Chronic Disease | 4 | 2022 | 959 | 0.850 |
Why?
|
| Health Expenditures | 1 | 2024 | 90 | 0.840 |
Why?
|
| Anxiety | 2 | 2024 | 312 | 0.820 |
Why?
|
| Insurance | 1 | 2022 | 12 | 0.810 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.800 |
Why?
|
| Hyperthyroidism | 1 | 2022 | 75 | 0.790 |
Why?
|
| Cost-Benefit Analysis | 8 | 2024 | 471 | 0.790 |
Why?
|
| Metformin | 2 | 2024 | 128 | 0.780 |
Why?
|
| Outpatients | 1 | 2022 | 103 | 0.770 |
Why?
|
| Systems Integration | 2 | 2021 | 36 | 0.770 |
Why?
|
| Quality-Adjusted Life Years | 7 | 2024 | 145 | 0.770 |
Why?
|
| Schools, Medical | 1 | 2023 | 136 | 0.760 |
Why?
|
| Hospitalization | 3 | 2021 | 898 | 0.760 |
Why?
|
| Health Services Accessibility | 4 | 2021 | 438 | 0.760 |
Why?
|
| Referral and Consultation | 1 | 2024 | 349 | 0.750 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 229 | 0.750 |
Why?
|
| Quality of Life | 7 | 2021 | 1687 | 0.740 |
Why?
|
| Patient Preference | 2 | 2025 | 117 | 0.720 |
Why?
|
| Thyroid Hormones | 2 | 2023 | 341 | 0.720 |
Why?
|
| Financing, Organized | 1 | 2020 | 12 | 0.700 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2020 | 24 | 0.690 |
Why?
|
| Breast Density | 1 | 2020 | 35 | 0.680 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 232 | 0.680 |
Why?
|
| State Health Plans | 1 | 2019 | 13 | 0.660 |
Why?
|
| Program Evaluation | 1 | 2020 | 311 | 0.640 |
Why?
|
| Hypertension | 3 | 2016 | 746 | 0.630 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 360 | 0.620 |
Why?
|
| Early Medical Intervention | 1 | 2018 | 20 | 0.620 |
Why?
|
| Quality of Health Care | 3 | 2022 | 387 | 0.620 |
Why?
|
| Veterans | 1 | 2019 | 86 | 0.610 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 283 | 0.600 |
Why?
|
| Community Health Centers | 2 | 2022 | 116 | 0.590 |
Why?
|
| Medicare | 4 | 2024 | 428 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2024 | 566 | 0.560 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 431 | 0.550 |
Why?
|
| Public Health | 2 | 2021 | 140 | 0.540 |
Why?
|
| Quality Improvement | 2 | 2017 | 459 | 0.540 |
Why?
|
| Health Policy | 2 | 2016 | 191 | 0.530 |
Why?
|
| Communication | 1 | 2020 | 462 | 0.530 |
Why?
|
| Thyroxine | 5 | 2024 | 361 | 0.530 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 4 | 0.530 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 332 | 0.520 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 422 | 0.510 |
Why?
|
| Surveys and Questionnaires | 10 | 2025 | 2667 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 307 | 0.510 |
Why?
|
| Thyrotropin | 4 | 2024 | 292 | 0.500 |
Why?
|
| Risk Assessment | 5 | 2024 | 2335 | 0.490 |
Why?
|
| Attitude to Health | 1 | 2016 | 220 | 0.490 |
Why?
|
| Glucose | 3 | 2022 | 633 | 0.490 |
Why?
|
| HIV Infections | 1 | 2024 | 857 | 0.490 |
Why?
|
| Medication Adherence | 1 | 2016 | 139 | 0.480 |
Why?
|
| Insurance Coverage | 2 | 2019 | 126 | 0.470 |
Why?
|
| Opioid-Related Disorders | 3 | 2022 | 194 | 0.470 |
Why?
|
| Leadership | 2 | 2017 | 143 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1054 | 0.450 |
Why?
|
| Obesity | 2 | 2011 | 974 | 0.450 |
Why?
|
| Preventive Health Services | 1 | 2014 | 39 | 0.450 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3691 | 0.450 |
Why?
|
| Health Care Reform | 2 | 2015 | 85 | 0.440 |
Why?
|
| Coronary Disease | 1 | 2014 | 261 | 0.410 |
Why?
|
| Bariatric Surgery | 2 | 2017 | 200 | 0.410 |
Why?
|
| Disease Progression | 4 | 2024 | 1485 | 0.400 |
Why?
|
| Comorbidity | 5 | 2018 | 955 | 0.380 |
Why?
|
| Models, Economic | 3 | 2024 | 62 | 0.360 |
Why?
|
| Sodium | 2 | 2022 | 334 | 0.360 |
Why?
|
| Informed Consent | 2 | 2023 | 276 | 0.360 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 112 | 0.360 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 170 | 0.340 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2024 | 55 | 0.340 |
Why?
|
| Young Adult | 7 | 2024 | 6412 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 225 | 0.330 |
Why?
|
| Markov Chains | 2 | 2020 | 128 | 0.310 |
Why?
|
| Insulin | 3 | 2024 | 1152 | 0.310 |
Why?
|
| Prospective Studies | 7 | 2024 | 4345 | 0.310 |
Why?
|
| Monte Carlo Method | 2 | 2020 | 187 | 0.310 |
Why?
|
| Risk Factors | 6 | 2024 | 5577 | 0.310 |
Why?
|
| Hypoglycemia | 2 | 2024 | 109 | 0.300 |
Why?
|
| Life Expectancy | 3 | 2023 | 88 | 0.290 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 66 | 0.280 |
Why?
|
| California | 5 | 2025 | 150 | 0.270 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 6808 | 0.270 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 2782 | 0.260 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 54 | 0.260 |
Why?
|
| Attitude of Health Personnel | 3 | 2022 | 651 | 0.260 |
Why?
|
| Chronic Pain | 2 | 2022 | 166 | 0.250 |
Why?
|
| Job Satisfaction | 2 | 2018 | 79 | 0.240 |
Why?
|
| Deprescriptions | 1 | 2025 | 9 | 0.240 |
Why?
|
| Costs and Cost Analysis | 3 | 2020 | 153 | 0.240 |
Why?
|
| Health Care Surveys | 2 | 2019 | 279 | 0.240 |
Why?
|
| Triiodothyronine | 2 | 2023 | 349 | 0.240 |
Why?
|
| Colorado | 1 | 2024 | 37 | 0.230 |
Why?
|
| Chicago | 2 | 2024 | 1438 | 0.230 |
Why?
|
| Health Care Costs | 3 | 2024 | 237 | 0.230 |
Why?
|
| Internship and Residency | 2 | 2011 | 1066 | 0.230 |
Why?
|
| Retrospective Studies | 6 | 2024 | 9310 | 0.230 |
Why?
|
| Self-Management | 1 | 2024 | 42 | 0.230 |
Why?
|
| Longitudinal Studies | 4 | 2025 | 1085 | 0.230 |
Why?
|
| Efficiency | 2 | 2021 | 40 | 0.220 |
Why?
|
| Physician-Patient Relations | 3 | 2016 | 625 | 0.220 |
Why?
|
| Logistic Models | 2 | 2019 | 1216 | 0.210 |
Why?
|
| Urban Population | 1 | 2024 | 225 | 0.210 |
Why?
|
| Parental Leave | 1 | 2023 | 11 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 104 | 0.210 |
Why?
|
| Prevalence | 2 | 2019 | 1251 | 0.210 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 5 | 0.210 |
Why?
|
| Insurance, Health | 2 | 2015 | 164 | 0.210 |
Why?
|
| Faculty | 1 | 2023 | 34 | 0.210 |
Why?
|
| Analgesics, Opioid | 3 | 2022 | 451 | 0.210 |
Why?
|
| Academic Medical Centers | 3 | 2023 | 387 | 0.200 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 48 | 0.200 |
Why?
|
| Organizational Policy | 1 | 2023 | 55 | 0.200 |
Why?
|
| Suicide | 1 | 2024 | 151 | 0.200 |
Why?
|
| Antipsychotic Agents | 1 | 2023 | 139 | 0.200 |
Why?
|
| Fee-for-Service Plans | 1 | 2022 | 30 | 0.200 |
Why?
|
| Buprenorphine | 1 | 2022 | 41 | 0.200 |
Why?
|
| Waiting Lists | 1 | 2023 | 189 | 0.190 |
Why?
|
| Adolescent | 4 | 2024 | 9341 | 0.190 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 103 | 0.190 |
Why?
|
| Dementia | 1 | 2023 | 205 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2020 | 878 | 0.170 |
Why?
|
| Computers | 1 | 2020 | 111 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 125 | 0.170 |
Why?
|
| Opiate Substitution Treatment | 1 | 2020 | 41 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 845 | 0.170 |
Why?
|
| Time Factors | 4 | 2021 | 5362 | 0.170 |
Why?
|
| Pandemics | 2 | 2023 | 788 | 0.170 |
Why?
|
| Fasting | 1 | 2020 | 166 | 0.170 |
Why?
|
| Emotions | 1 | 2023 | 358 | 0.170 |
Why?
|
| Hospitals | 1 | 2022 | 308 | 0.170 |
Why?
|
| Blood Pressure | 2 | 2015 | 906 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 117 | 0.160 |
Why?
|
| Demography | 2 | 2023 | 183 | 0.160 |
Why?
|
| Length of Stay | 1 | 2022 | 756 | 0.160 |
Why?
|
| Internal Medicine | 4 | 2021 | 364 | 0.150 |
Why?
|
| United Kingdom | 2 | 2024 | 167 | 0.150 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 20 | 0.150 |
Why?
|
| Electronic Health Records | 2 | 2021 | 355 | 0.150 |
Why?
|
| Work Engagement | 1 | 2017 | 6 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2023 | 193 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2023 | 2893 | 0.150 |
Why?
|
| Inservice Training | 1 | 2017 | 38 | 0.150 |
Why?
|
| Poverty | 1 | 2019 | 185 | 0.140 |
Why?
|
| Urban Health Services | 1 | 2017 | 44 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 330 | 0.140 |
Why?
|
| Patient Participation | 1 | 2019 | 227 | 0.140 |
Why?
|
| Cost Savings | 1 | 2017 | 71 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 497 | 0.140 |
Why?
|
| Diet Therapy | 1 | 2016 | 20 | 0.140 |
Why?
|
| Financing, Personal | 1 | 2016 | 21 | 0.130 |
Why?
|
| Perception | 1 | 2017 | 181 | 0.130 |
Why?
|
| Linear Models | 2 | 2018 | 422 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2016 | 37 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2016 | 85 | 0.130 |
Why?
|
| Overweight | 1 | 2017 | 118 | 0.130 |
Why?
|
| Sexual and Gender Minorities | 1 | 2019 | 220 | 0.130 |
Why?
|
| Medical Overuse | 1 | 2016 | 36 | 0.130 |
Why?
|
| Drug Monitoring | 1 | 2016 | 118 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 806 | 0.130 |
Why?
|
| Life Style | 1 | 2016 | 174 | 0.130 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1882 | 0.120 |
Why?
|
| Data Accuracy | 1 | 2015 | 32 | 0.120 |
Why?
|
| Phenotype | 1 | 2021 | 2465 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2018 | 1499 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 463 | 0.120 |
Why?
|
| Federal Government | 1 | 2014 | 29 | 0.120 |
Why?
|
| Health Surveys | 2 | 2013 | 239 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 234 | 0.110 |
Why?
|
| Medically Uninsured | 1 | 2014 | 62 | 0.110 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 228 | 0.110 |
Why?
|
| Primary Prevention | 2 | 2013 | 82 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2018 | 1103 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2015 | 328 | 0.110 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 10 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 360 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2014 | 679 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2017 | 775 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 279 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2022 | 8367 | 0.100 |
Why?
|
| Registries | 2 | 2013 | 812 | 0.100 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 61 | 0.090 |
Why?
|
| Medical Audit | 1 | 2011 | 39 | 0.090 |
Why?
|
| Burnout, Professional | 1 | 2013 | 102 | 0.090 |
Why?
|
| Health Status | 2 | 2023 | 370 | 0.090 |
Why?
|
| Prognosis | 2 | 2016 | 3810 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2010 | 162 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 214 | 0.080 |
Why?
|
| Disease Management | 1 | 2011 | 332 | 0.080 |
Why?
|
| Counseling | 1 | 2009 | 167 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2019 | 0.070 |
Why?
|
| Stroke | 1 | 2015 | 1002 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 364 | 0.070 |
Why?
|
| Brazil | 1 | 2024 | 75 | 0.060 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 10 | 0.060 |
Why?
|
| Calibration | 1 | 2024 | 103 | 0.060 |
Why?
|
| Insulin Glargine | 1 | 2023 | 12 | 0.060 |
Why?
|
| Algorithms | 1 | 2011 | 1917 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2023 | 121 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2022 | 5 | 0.050 |
Why?
|
| Dronabinol | 1 | 2023 | 56 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 152 | 0.050 |
Why?
|
| Methadone | 1 | 2022 | 46 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2022 | 69 | 0.050 |
Why?
|
| Systems Analysis | 1 | 2021 | 17 | 0.050 |
Why?
|
| Naltrexone | 1 | 2022 | 138 | 0.050 |
Why?
|
| Jurisprudence | 1 | 2021 | 25 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 382 | 0.040 |
Why?
|
| Community Networks | 1 | 2021 | 30 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 491 | 0.040 |
Why?
|
| Social Stigma | 1 | 2019 | 72 | 0.040 |
Why?
|
| Survival Rate | 2 | 2014 | 1899 | 0.040 |
Why?
|
| Economics, Medical | 1 | 2018 | 6 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 303 | 0.040 |
Why?
|
| Mental Health | 1 | 2019 | 181 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 1797 | 0.040 |
Why?
|
| Checklist | 1 | 2018 | 65 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 102 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 604 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 149 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 27656 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 234 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 22 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 48 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 50 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 590 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 593 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1708 | 0.030 |
Why?
|
| Clinical Audit | 1 | 2013 | 9 | 0.030 |
Why?
|
| New York City | 1 | 2013 | 61 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 898 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2013 | 83 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 26 | 0.030 |
Why?
|
| Family Practice | 1 | 2013 | 84 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 982 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 170 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 198 | 0.020 |
Why?
|
| Medical Errors | 1 | 2013 | 115 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 2317 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2013 | 232 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1593 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1870 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 377 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2009 | 329 | 0.020 |
Why?
|